Verteporfin Photodynamic Therapy Cohort Study: Report 1: Effectiveness and Factors Influencing Outcomes

Ophthalmology

Volumn 116, Issue 12, 2009, Pages

  Harding, Simon P ^a   Tomlin, Keith ^b   Reeves, Barnaby C ^b   Langham, Julia ^b   Walker, Jemma ^b   Carpenter, James ^b   Grieve, Richard ^b   Patton, William P ^c   Muldrew, Katherine A ^c   Peto, Tunde ^d   Chakravarthy, Usha ^c  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VERTEPORFIN;

AGE; AGED; ARTICLE; CONTRAST SENSITIVITY; DETERIORATION; DRUG EXTRAVASATION; FEMALE; HUMAN; INJECTION SITE PAIN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; SIDE EFFECT; SMOKING; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UNITED KINGDOM; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 70549090079     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.10.022     Document Type: Article

References (15)

1. Klein R., Klein B.E., and Linton K.L. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 99 (1992) 933-943
2. Vingerling J.R., Dielemans I., Hofman A., et al. The prevalence of age-related maculopathy in the Rotterdam study. Ophthalmology 102 (1995) 205-210
3. Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials. TAP report 1. Arch Ophthalmol 117 (1999) 1329-1345
4. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report 2. Arch Ophthalmol 119 (2001) 198-207
5. National Institute for Clinical Excellence. Macular degeneration (age-related)-photodynamic therapy. The clinical effectiveness and cost effectiveness of photodynamic therapy for age-related macular degeneration. September 2003. Technology Appraisals TA68. http://www.nice.org.uk/guidance/TA68 Accessed October 6, 2009
6. The Verteporfin Photodynamic Therapy Cohort Study for the United Kingdom. Manual of Operations version 2.1 (December 2005) 15-91. http://www.lshtm.ac.uk/hsru/vpdt/publications/Manop_v21_211205.pdf Accessed October 6, 2009
7. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics: ETDRS report number 7. Ophthalmology 98 suppl (1991) 741-756
8. Pelli D.G., Robson J.G., and Wilkins A.J. The design of a new letter chart for measuring contrast sensitivity. Clin Vis Sci 2 (1988) 187-199
9. Ali F., Chan W.C., Stevenson M.R., et al. Morphometric analysis of angiograms of exudative lesions in age-related macular degeneration. Arch Ophthalmol 122 (2004) 710-715
10. Hogg R., Curry E., Muldrew A., et al. Identification of lesion components that influence visual function in age-related macular degeneration. Br J Ophthalmol 87 (2003) 609-614
11. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report no. 3. Arch Ophthalmol 120 (2002) 1443-1454
12. Thorpe K.E., Zwarenstein M., Oxman A.D., et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 62 (2009) 464-475
13. Doris N., Hart P.M., Chakravarthy U., et al. Relation between macular morphology and visual function in patients with choroidal neovascularisation of age-related macular degeneration. Br J Ophthalmol 85 (2001) 184-188
14. El Mallah M.K., Chakravarthy U., and Hart P.M. Amblyopia: is visual loss permanent?. Br J Ophthalmol 84 (2000) 952-956
15. Swets J., Tanner Jr. W.P., and Birdsall T.G. Decision processes in perception. Psychol Rev 68 (1961) 301-340